Naveen Pemmaraju: Final Results for Tagraxofusp in R/R Myelofibrosis
Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues, published in Blood Neoplasia:
“Proud to share our brand new collaborative paper just out in Blood Journals Portfolio.
Final clinical trial results for our Tagraxofusp CD123-Targeted therapy Ph 1/2 program for patients with R/R Myelofibrosis || MPNSM | Yacoub and H Ali and Naveen Pemmaraju.”
Title: Final Safety and Efficacy Results from a Phase 1/2 Study of Tagraxofusp, a CD123-Targeted Therapy, for Myelofibrosis
Authors: Abdulraheem Yacoub, Haris Ali, Vikas Gupta, Eunice S. Wang, Mrinal M. Patnaik, Gary J. Schiller, Minakshi Taparia, Tariq I. Mughal, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju
You can read the Full Article on Blood Neoplasia.
More posts featuring Naveen Pemmaraju.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023